Open an account

Optimi Health

OPTH · CANADIAN

$3.25−$0.03 (−0.91%)TodayMarket closed ·
Prev close $3.28

About OPTH

Optimi Health Corp. functions as an end-to-end GMP manufacturer and supplier of psychedelic substances. With its vertically integrated approach, the Company owns and operates two purpose built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada. Additionally, it holds a Dealer’s Licence under Canada’s Narcotic Control Regulations, allowing the Company to possess, produce, assemble, sell and deliver psilocybin and other psychedelic substances within the regulated framework set forth by Health Canada.

Employees
9
Headquarters
Vancouver, British Columbia
Listed
Feb 25, 2021
Sector
N/A
Industry
N/A
Website
optimihealth.ca

OPTH key statistics

Market cap
26.51M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
28.73K
Volume
6.25K
Open price
$3.28
High today
$3.37
Low today
$3.16
52 Week high
$8.84
52 Week low
$3.04

Optimi Health (OPTH) at a glance

Optimi Health (OPTH) last traded at $3.25, with a market cap of 26.51M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.16 and $3.37. The current price is 2.8% above the day's low and 3.6% below its high.

Volume so far is 6.25K shares, below the average of 28.73K shares a day.

Over the past year Optimi Health has ranged from $3.04 to $8.84, and now sits 4% of the way up that range.

Optimi Health met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q3 FY26 it reported -$0.56 per share against an estimate of -$0.408.

OPTH earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q2 FY26: reported -$0.98 per share against an estimate of -$0.3672
  2. Q3 FY26: reported -$0.56 per share against an estimate of -$0.408

OPTH news

  • Press releaseGlobe Newswire

    Optimi Health to Present at the ThinkEquity Conference

  • Press releaseGlobe Newswire

    Optimi Health Appoints Melanie Pump to Board of Directors

  • Rishabh Mishra

    Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

  • Press releaseGlobe Newswire

    Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

  • Press releaseGlobe Newswire

    Optimi Health Establishes Discretionary Equity Facility

  • Press releasePRNewswire

    Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

  • Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025

  • Press releaseGlobe Newswire

    Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.